<DOC>
	<DOCNO>NCT00661999</DOCNO>
	<brief_summary>RATIONALE : Darbepoetin alfa may cause body make red blood cell . Red blood cell contain iron need carry oxygen tissue . It yet know whether give darbepoetin alfa ( DA ) together intravenous iron oral iron effective give darbepoetin alfa together placebo treat anemia cause chemotherapy . PURPOSE : This randomized phase III trial study give darbepoetin alfa together iron see well work compare give darbepoetin alfa together placebo treat anemia cause chemotherapy patient cancer .</brief_summary>
	<brief_title>Darbepoetin Alfa With Without Iron Treating Anemia Caused By Chemotherapy Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary * To compare effect IV iron , oral iron , placebo combination darbepoetin alfa hematopoietic response rate , define hemoglobin increment ≥ 2.0 g/dL baseline achievement hemoglobin ≥ 11 g/dL absence red blood cell transfusion ( RBC ) precede 28 day treatment period , cancer patient chemotherapy-associated anemia . Secondary - To compare effect regimens mean hemoglobin increment baseline week 7 16 patient . - To compare effect regimens percentage patient maintain average hemoglobin level within American Society Hematology/American Society Clinical Oncology ( ASH/ASCO ) National Comprehensive Cancer Network ( NCCN ) guideline-based target hemoglobin range ( 11-13 g/dL ) , achieve hemoglobin ≥ 11 g/dL week 1 week 16 absence RBC transfusion precede 28 day treatment period . - To compare effect intravenously ( IV ) iron , oral iron , placebo response darbepoetin alfa , term time achieve hemoglobin level ≥ 11g/dL . - To compare effect regimens percentage patient require RBC transfusion total transfusion need . - To compare effect regimens change hemoglobin week week . - To compare effect regimens quality-of-life change baseline week 7 16 . - To identify patient inflammation ( indicate elevate C-reactive protein ( CRP ) serum hepcidin level low soluble transferrin receptor ( sTfR ) /log ferritin ratio ) respond differently darbepoetin alfa iron therapy patient without inflammation . OUTLINE : Patients stratify accord severity anemia ( mild [ hemoglobin ≥ 9.5 g/dL ] v severe [ hemoglobin &lt; 9.5 g/dL ] ) , treatment platinum-containing regimen ( yes v ) , gender . Patients randomize 1 3 treatment arm . - Arm I : Patients receive darbepoetin alfa subcutaneously sodium ferric gluconate complex IV 90 minute day 1 . - Arm II : Patients receive darbepoetin alfa arm I oral ferrous sulfate daily day 1-21 . - Arm III : Patients receive darbepoetin alfa arm I oral placebo daily day 1-21 . In arm , treatment repeat every 21 day 15 week absence unacceptable toxicity . Patients complete quality-of-life ( QOL ) questionnaires week 1 , 7 , 16 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonmyeloid cancer ( nonmelanomatous skin cancer ) Receiving schedule receive chemotherapy ( biological agent , small molecules/tyrosine kinase inhibitor antibodybased therapy , allow ) Has chemotherapyrelated anemia ( hemoglobin &lt; 11 g/dL ) No anemia know secondary gastrointestinal bleeding hemolysis No anemia know secondary vitamin B12 folic acid deficiency + Vitamin B12 folic acid deficiency must rule mean corpuscular volume ( MCV ) &gt; 100 fL No anemia secondary chemotherapyinduced myelodysplastic syndrome No primary hematologic disorder cause moderate severe anemia ( e.g. , congenital dyserythropoietic anemia , homozygous hemoglobin S disease compound heterozygous sickling state , thalassemia major ) Carriers disease state eligible No firstdegree relative primary hemochromatosis ( unless patient undergone HFE genotyping find least one wildtype allele , proband family demonstrate either common C282Y H63D mutation ) PATIENT CHARACTERISTICS : ECOG performance status 02 Ferritin &gt; 20 mcg/L ( i.e. , obviously iron deficient ) ALT AST &lt; 5 time upper limit normal Alert , mentally competent , able sign inform consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Willing able randomize undergo study treatment Willing able fill qualityoflife form No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] ≥ 180 mm Hg diastolic BP ≥ 100 mm Hg ) No history uncontrolled cardiac arrhythmia No pulmonary embolism deep venous thrombosis within past year ( unless patient anticoagulation therapy planning continue study participation ) No know hypersensitivity darbepoetin alfa , erythropoietin , mammalian cellderived product , iron , human albumin No seizure within past 3 month No gastrointestinal condition expect cause significant impairment oral iron , untreated celiac disease amyloidosis involve gut Patients celiac disease adhere glutenfree diet eligible PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 month since prior darbepoetin alfa , epoetin alfa , investigational form erythropoietin ( e.g. , geneactivated erythropoietin novel erythropoiesisstimulating protein ) More 1 year since prior peripheral blood stem cell bone marrow transplantation More 2 week since prior red blood cell transfusion More 14 day since prior major surgery No prior gastrectomy resection &gt; 100 cm small intestine Not plan undergo stem cell bone marrow transplantation within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>anemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
</DOC>